Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Other microRNA-122-responsive messenger RNAs (mRNAs) refer to the collective group of endogenous transcripts regulated by miR-122, a highly abundant, liver-specific microRNA (Jopling et al., 2005, Science). Under normal physiological conditions, miR-122 maintains hepatic homeostasis by binding to the 3' untranslated regions of these mRNAs, leading to their degradation or translational repression (Esau et al., 2006, Cell Metabolism). These responsive mRNAs are involved in critical pathways such as cholesterol biosynthesis, iron metabolism, and cell cycle regulation (Roberts et al., 2011, Nucleic Acids Research). In the context of Hepatitis C Virus (HCV) infection, miR-122 is uniquely required for viral replication by binding to the 5' UTR of the viral genome (Jopling et al., 2005, Science). Therapeutic agents like Miravirsen (SPC3649) and RG-101 are designed to sequester miR-122, which effectively inhibits HCV replication (Lanford et al., 2010, Science; Janssen et al., 2013, NEJM). A secondary effect of this sequestration is the 'de-repression' of host miR-122-responsive mRNAs, resulting in increased expression of their encoded proteins. This mechanism explains the observed reduction in serum cholesterol levels in patients treated with miR-122 inhibitors (Janssen et al., 2013, NEJM). However, the broad modulation of these mRNAs poses potential safety concerns, including long-term metabolic changes or the risk of promoting oncogenic pathways (Thibault et al., 2013, Nature Communications). Consequently, these mRNAs are studied as pharmacodynamic markers to assess the systemic impact of miR-122-targeted therapies.
Indirect modulation via sequestration of microRNA-122, leading to the de-repression and increased translation of target messenger RNAs.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Other microRNA-122-responsive messenger RNAs (miR-122-responsive mRNAs).